Atypical extended immune-related neutropenia in patient treated with pembrolizumab

Eur J Cancer. 2020 May:130:269-271. doi: 10.1016/j.ejca.2020.02.005. Epub 2020 Mar 17.

Authors

Pierre-Antoine Laurain¹, Térence Landrin², Sami Souidi², Philippe Beuzeboc³, Florian Scotté⁴

Affiliations

¹ Medical Oncology and Supportive Care, Hôpital Foch, 40 Rue Worth, 92150, Suresnes, France. Electronic address: pierreantoine.laurain@gmail.com.
² Medical Oncology and Supportive Care, Hôpital Foch, 40 Rue Worth, 92150, Suresnes, France.
³ Chief of Department of Medical Oncology and Supportive Care, Hôpital Foch, France.
⁴ Chief of Service of Medical Oncology and Supportive Care, Hôpital Foch, France.

PMID: 32192809
DOI: 10.1016/j.ejca.2020.02.005

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Female
Humans
Middle Aged
Neutropenia / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab